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S U M M A R Y
Schistosomiasis japonica has a long history in the Philippines. In 1975, 24 endemic provinces were
identiﬁed in the northern, central, and southern islands of the Philippines. More than ﬁve million people
were at risk, with approximately one million infected. In 2003, new foci of infection were found in two
provinces in the north and central areas. For the past 30 years, human mass drug administration (MDA),
utilizing the drug praziquantel, has been the mainstay of control in the country. Recent studies have
shown that the schistosomiasis prevalence ranges from 1% to 50% within different endemic zones. Severe
end-organ morbidity is still present in many endemic areas, particularly in remote villages with poor
treatment coverage. Moreover, subtle morbidities such as growth retardation, malnutrition, anemia, and
poor cognitive function in infected children persist. There is now strong evidence that large mammals
(e.g. water buffaloes, cattle) contribute signiﬁcantly to disease transmission, complicating control
efforts. Given the zoonotic nature of schistosomiasis in the Philippines, it is evident that the incidence,
prevalence, and morbidity of the disease will not be controlled by MDA alone. There is a need for
innovative cost-effective strategies to control schistosomiasis in the long term.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Schistosomiasis or bilharzia currently infects over 200 million
people worldwide and results in approximately 25 million
disability-adjusted life years lost.1–3 The disease is caused
predominantly by ﬁve blood ﬂuke species of the genus Schisto-
soma: S. mansoni, S. japonicum, S. mekongi, S. intercalatum, and S.
haematobium. Zoonotic transmission is a unique factor with S.
japonicum (and S. mekongi) infection, making control measures
more complicated (Figure 1). Over the last two decades schistoso-
miasis has been eradicated in Japan and in the coastal plain of the
People’s Republic of China, by way of comprehensive multidisci-     
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http://dx.doi.org/10.1016/j.ijid.2013.09.011plinary campaigns. However, transmission continues in the lake
and marshland regions below the Yangtze River and in the
mountainous areas of Sichuan and Yunnan Provinces. The disease
remains highly endemic in the Philippines and to a lesser extent in
isolated pockets in Indonesia.4–8
The ﬁrst case of schistosomiasis in the Philippines was reported
in 1906.9 The case was a Filipino man who had never been out of
the country. He eventually died with clinical impressions of
amebiasis and bacterial infection. Autopsy conﬁrmed the diagnosis
of amebiasis, but with additional ﬁndings of Schistosoma ova in
sections of the large intestine, liver, and lungs. Subsequently,
schistosome ova were found in several cases among 500 autopsies
reported in 1908 and in the feces of some prisoners admitted to
Bilibid Prison, in the City of Manila in 1914.10 Several years later, in
1928, a case of Katayama disease (a toxemic syndrome with fever
in the acute, early egg-laying phase of schistosomiasis) presenting
as chronic appendicitis was reported.11 Attempts to demonstrate
the intermediate host of the parasite were not successful until the
discovery of the snail Oncomelania hupensis quadrasi in Palo, Leyteociety for Infectious Diseases. Open access under CC BY-NC-SA license.
Figure 1. The zoonotic lifecycle of Schistosoma japonicum in the Philippines.
Figure 2. Map of the current schistosome-endemic areas in the Philippines
highlighted in blue. The red dot represents a new focus of infection discovered in
2003.
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was then established by infecting the animals with cercariae
(Schistosoma larvae) obtained from the Oncomelania snails
(Figure 1).
Following identiﬁcation of the intermediate host, research on
delineating schistosomiasis-endemic areas and studies on the
clinical and pathological aspects of schistosomiasis japonica were
conducted. Research activities were disrupted during World War II,
but were given impetus when an outbreak of schistosomiasis
occurred among Americans and the Allied Armed Forces, who
landed on the island of Leyte in 1945.13 In 1953, schistosomiasis
was recognized as a public health problem in the Philippines. From
the early 1960s to the latter part of the 1970s, extensive research
activities ranging from studies on parasite biology, transmission,
and control to clinical and pathological aspects of the disease were
carried out. Morphological characteristics and the biology of O.
hupensis quadrasi cercarial shedding patterns, and survival in the
environment, and studies elucidating the lifecycle of the parasite
were documented. In 1975 S. japonicum-endemic regions in the
Philippines were determined.14 It was estimated that ﬁve million
people lived in schistosomiasis-endemic areas, with over 800 000
individuals with active infection. The major foci of schistosomiasis
were in the islands of Leyte, Samar, and Mindanao, which cover 24
provinces of eight regions of the country, and this situation
remains today (Figure 2). These endemic regions have no distinct
dry season. The region comprises predominantly rice growing
areas, which maximize contact between humans and fresh water
snails.14 In 2003, new foci of infection were found in the provinces
of Negros Occidental and in Cagayan in the north of the country15
(Figure 2).2. Morbidity due to S. japonicum infection
Clinical manifestations of schistosomiasis japonica among
residents in endemic communities, non-immune individuals,
and hospitalized patients, have been reported.13,16 Three clinical
stages in schistosomiasis japonica infection in the Philippines are
recognized and classiﬁed: the ﬁrst or early phase, the second or
acute phase, and the third or chronic phase.16,17
2.1. Early phase
The ﬁrst stage includes the period from cercarial penetration to
establishment of paired worms in the mesenteric venules.
Exposure to cercariae via fresh water contact immediately (but
not necessarily) results in pruritus, erythema, and a papular rash
known as ‘swimmer’s itch’. People living in endemic areas are
seldom seen with the erythema and papular rashes. However, in
non-immune individuals, the incidence is highly variable. For
instance, among 158 American soldiers landing on the island of
Leyte during World War II, 9% showed signs and symptoms of
swimmer’s itch.18 During the period corresponding to larval
migration, infected individuals may have chills, fever, headache, an
unproductive cough due to pulmonary involvement, and abdomi-
nal cramps. The time of onset and intensity of the above clinical
manifestations varies widely.19
2.2. Acute phase
Maturation and pairing of adult worms along with the onset of
oviposition 42–70 days post-exposure, leads to the second or
acute phase of the disease. At this stage, worm metabolic products
that are expelled into the systemic circulation contribute to a
serum sickness-like condition called Katayama syndrome.20 This
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who were affected by schistosomiasis during the Leyte cam-
paign.18 Moderate to severe disease is characterized by marked
eosinophilia, malaise, generalized muscle pain, and pulmonary
symptoms and lymphadenopathy. Tender hepatomegaly was
seen in 92% of the soldiers and splenomegaly occurred in 30% of
the cases. Diarrhea or dysentery was seen in about 67% of the
men.18,20 Neurological symptoms suggestive of meningoenceph-
alitis were seen in 9.3%.18 The severity of clinical disease was also
noted to be correlated with the intensity of infection.18
2.3. Chronic phase
During chronic schistosome infection, a variety of clinical
manifestations may result from infection depending on the organ
involved, and these range from mild to severe, with several
gradations in between. Sequelae are categorized into hepatosple-
nic, hepatointestinal, pulmonary, cerebral, and ectopic forms.17,21
Cardiac and renal localizations of lesions are rarely encountered.
In the hepatosplenic form, hemodynamic changes are due to S.
japonicum eggs trapped in the presinusoidal areas of the liver.
These eggs induce classical pipe-stem ﬁbrosis (PSF) around the
intrahepatic radicals of the portal vein, leading to increases in
splenic pulp and portal vein pressures and signs of severe portal
hypertension.22 The severity of portal hypertension correlates with
the severity of ﬁbrosis as demonstrated by Doppler ultrasonogra-
phy.23 Patients with severe periportal thickening have dilated
portal and splenic veins, high portal vein velocity, and portal vein
collateral formation. Recently we conducted community-based
ultrasound examinations in endemic villages in Northern Samar
Province to determine the prevalence of schistosomiasis-induced
hepatic ﬁbrosis and hepatosplenic disease. Individuals within
these villages have been receiving annual mass drug administra-
tion (MDA) with praziquantel for more than 10 years. Approxi-
mately 50% of the individuals have some form of hepatic ﬁbrosis,
with 20% having grade III ﬁbrosis (severe ﬁbrosis) according to the
World Health Organization (WHO) staging criteria (unpublished
data). The chronic pulmonary form is due to eggs that have reached
the pulmonary circulation as emboli via the portosystemic
collaterals. The eggs obstruct the arterioles or pass through the
walls and lie in the parenchyma just outside the vessels, giving rise
to two types of lesions, namely arterial and parenchymatous
lesions, and this can lead to pulmonary hypertension or cor
pulmonale. Bronchial asthma, bronchitis, bronchiectasis, and
pulmonary emphysema have also been associated with schistoso-
miasis.13,17
Chronic schistosomiasis of the central nervous system can
present clinically with a wide spectrum of signs and symptoms
including: headache, nausea, vertigo, visual and speech defects,
rigidity, spasm, mental confusion, and hemiplegia.13,17 Focal
epilepsy due to schistosomiasis in the Philippines has been
estimated to be from 2% to 5% among S. japonicum-infected
individuals.13 Ectopic forms of schistosomiasis have been demon-
strated in many organs, including the heart, appendix, ovary,
fallopian tubes, and uterus.13,17
2.4. Other manifestations
Over the past 20 years, many studies have examined the impact
of S. japonicum infection on growth, nutrition, hemoglobin levels,
and cognitive functions in Filipino children. For example, in 1990 it
was demonstrated that the intensity of infection was associated
with decreased fat, muscle, and long bone growth in adolescents;
males aged 16 to 18 years were 7.8 cm shorter and 5.8 kg lighter
than non-infected adolescents in the same community.24,25 The
effects were greater in villages not yet receiving annual screeningand treatment. In other studies, S. japonicum infection in children
was associated with malnutrition, anemia, and lower cognitive
performance, such as learning, memory, and verbal ﬂuency.26–28
Studies in infected women have shown that maternal schistoso-
miasis has adverse effects on pregnancy outcomes. Babies born
from mothers with schistosomiasis have markedly decreased birth
weights. Circulating mediators of inﬂammation are elevated in the
peripheral blood, placental blood, and placental tissues of S.
japonicum-infected pregnant women. In addition, placental
interferon gamma is associated with both S. japonicum infection
status and markedly decreased birth weight.29
2.5. Chemotherapy
Praziquantel has proven to be effective against the ﬁve species
of schistosomes affecting humans. However, efﬁcacy depends on
the treatment dose. In an attempt to optimize praziquantel use for
the treatment of schistosomiasis, the WHO Special Programme for
Research and Training in Tropical Diseases (TDR) launched in 2003
a series of multi-country trials, comparing the efﬁcacy and safety of
40 mg/kg and 60 mg/kg in schistosome-infected patients in Asia,
Africa, and the Americas. In the clinical trial in the Philippines, the
40 mg/kg dose was effective and better tolerated than the higher
60 mg/kg dose. The national policy-makers in the Philippines
subsequently adopted the 40 mg/kg dose for its MDA program
against schistosomiasis. However, those found infected by stool
examination (case ﬁnding) were treated with 60 mg/kg and given
the same dose 2 weeks later as per the national protocol.
3. Past and present control strategies
The schistosomiasis problem in the Philippines is a formidable
one. Climatic conditions and rice farming methods have made snail
control difﬁcult. Before the introduction of praziquantel in the
Philippines, approaches used were aimed at decreasing transmis-
sion by reducing the number of snail intermediate hosts and by
limiting human exposure to the infective form of the parasite.
Environmental manipulation (e.g., irrigation) in combination with
molluscicides was used. However, these approaches were reported
to be expensive and have shown limited impact on human
transmission in pilot studies.30 Improved sanitation was an
essential component of the control program, but was difﬁcult to
sustain in communities, as no more than one third of the
population had satisfactory latrines. Chemotherapy was used only
on a case-by-case basis, as the drugs available at that time
produced signiﬁcant side effects before therapeutic levels were
reached. There were signiﬁcant achievements, but they were not
effective in reducing the prevalence, incidence, or morbidity of S.
japonicum infection.
With the introduction of praziquantel in the Philippines in
1980, schistosomiasis control shifted to a chemotherapy-based
program. Case ﬁnding and treatment led to a decline in the national
prevalence of schistosomiasis. In 1990 the Philippine National
Schistosomiasis Control Program (PNSCP) under the Philippine
Health Development Plan received a substantial loan, enabling the
PNSCP to intensify case ﬁnding and treatment in all endemic areas.
The PNSCP managed to reduce the national prevalence from more
than 10% before 1990 to less than 5% in 1995. Unfortunately, the
funds ceased in 1995. Subsequent marked budget reductions
resulted in signiﬁcantly decreased ﬁnancial support and a loss of
schistosomiasis control teams in each of the endemic municipali-
ties.31 After 1995 the chemotherapy-based control program
shifted from case ﬁnding and treatment to MDA. Despite the
marked reduction in ﬁnancial and manpower support for the
control program, the annual national prevalence data on schisto-
somiasis in the Philippines reported by the PNSCP has been
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data has given the mistaken impression that schistosomiasis is
no longer a major public health problem there and can even be
eliminated in some endemic areas by MDA. However, bodies of
evidence generated from endemic areas in the country are
suggesting that elimination of schistosomiasis in the Philippines
using MDA as the major approach will not be sustainable in the
long run. For example, in a study looking at the long-term impact
of intensive case ﬁnding treatment with praziquantel (compli-
ance more than 85% throughout the 9-year period of the study),
dramatic drops in the prevalence and incidence of infection
occurred in the ﬁrst 3 to 4 years, followed by signiﬁcant
rebound.32
Recent studies by Leonardo and colleagues,33,34 funded by the
WHO Western Paciﬁc Region (WPRO), reported that the national
schistosomiasis prevalence in the Philippines is less than 1% (mean
0.49%; range 0.08–3.95%). However, these ﬁndings grossly under-
state the current human schistosomiasis prevalence there. We
recently (2011) conducted a cross-sectional epidemiological
survey to determine the current schistosomiasis burden across
six barangays in Northern Samar, the Philippines. The overall
human prevalence was found to be 26.4% (n = 1955; 95%
conﬁdence interval 24.5–28.4%), while in carabao (water buffa-
loes) it was found to be 65.4% (n = 211; 95% conﬁdence interval
58.9–71.9%).35 The study was expanded in 2012 to 18 barangays,
and the human schistosomiasis prevalences in the barangays
under study were found to range from 5% to 48%.35 The results are
contrary to those recently reported for Northern Samar where the
mean human prevalence was reported to be only 2.45%.33,34
Advanced schistosomiasis cases and deaths are now being
reported by the media and conﬁrmed by the National Department
of Health for Mindanao, Samar, Leyte, and Oriental Mindoro.35 This
latest evidence clearly demonstrates that schistosomiasis has not
been eliminated from the Philippines and, indeed, remains a major
public health problem there. Moreover, the compliance to MDA has
decreased over time as people living in endemic villages in the
Philippines prefer case ﬁnding and treatment to MDA done
empirically.36–38 There are now strong bodies of evidence to show
that water buffalo (called carabao in the Philippines), cattle, dogs,
and a range of feral animals, also contribute signiﬁcantly to disease
transmission.39–43 Given the zoonotic nature of schistosomiasis in
the Philippines, there is a need for cheap innovative control
strategies to combat the disease.
4. Future control strategies leading to elimination
Over the last ﬁve decades, schistosomiasis japonica has been
eliminated from Japan (in 1996) and transmission has been
interrupted in the coastal plain region of the People’s Republic of
China, by integrated approaches involving snail control, mass
chemotherapy of the human population, health education,
provision of sanitary facilities, environmental modiﬁcation, and
improved farming methods. The successful schistosomiasis control
measures deployed in Japan and China cannot be easily duplicated
in the Philippines given the nature of year-round transmission
there (only 5 months in China) and limited health care dollars to
combat the disease.
The current (2012) national funding for schistosomiasis control
in the Philippines is PHP $ 47 684 000 (USD $ 1 126 477.54).25 This
amount represents only a small fraction (<1%) of what is currently
spent on the national schistosomiasis elimination program in
China.35 Moreover, the manpower and infrastructure in China far
surpass those of the Philippines. In the Philippines, the population
in rural endemic areas is growing exponentially; thus more and
more individuals are becoming at risk of contracting schistosomi-
asis. Filipinos residing within schistosomiasis-endemic areas aretypically very poor rice farmers with family incomes far below the
national average.35 Over 50% of the endemic population live in
poverty, with rudimentary water, sanitation, and hygiene;
therefore, the rates of parasitic diseases, acute respiratory
infections, diarrheal diseases, and other communicable diseases
are high.35 The only way forward is to break the S. japonicum
lifecycle through multi-component integrated control.
The disappointing results obtained with MDA for schistosomi-
asis control reﬂect the complex nature of the human–schistosome
parasite interaction. There is a need to formulate innovative
approaches that are economically sustainable in the Philippines.
Currently, a combination of human mass treatment, targeted
molluscicides, and bovine (water buffalo and cattle) treatment and
vaccination is being trialed in 22 highly endemic villages in the
province of Northern Samar. In a pre-clinical trial in China, the
vaccine (SjCTPI-Hsp70 construct) provided a 51.2% reduction in
worm burden, a 61.5% reduction in liver eggs, and a 52.1%
reduction in fecal eggs and hatching of fecal miracidia (free
swimming larvae).44 If the bovine vaccine, along with the other
integrated measures, proves to be successful, it may lead to
sustainable schistosomiasis control and elimination in the
Philippines.
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